Qiagen NVXTER:QIA -1.01%69 Days Payable is 37.46 as of Mar. 2026, which is 19% below its 10-year median of 46.24. GuruFocus rates XTER:QIA with a GF Score™ of 69/100 and a GF Value™ of €45.46 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Qiagen NV ranks worse than 76.32% on this metric.
Qiagen NV's average Accounts Payable for the
three
months ended in Mar. 2026 was €65 Mil. Qiagen NV's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €158 Mil.
Hence, Qiagen NV's Days Payable for the
three
months ended in Mar. 2026 was 37.46.
The historical rank and industry rank for Qiagen NV's Days Payable or its related term are showing as below:
XTER:QIA'
s Days Payable Range Over the Past 10 Years
Min: 30.23 Med: 46.24 Max: 58.08
Current: 34.53
During the past 13 years, Qiagen NV's highest Days Payable was 58.08. The lowest was 30.23. And the median was 46.24.
XTER:QIA's Days Payable is ranked worse than 76.32% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.385
vs XTER:QIA: 34.53
Qiagen NV's Days Payable
declined
from Mar. 2025 (40.63) to Mar. 2026 (37.46).
It may suggest that Qiagen NVaccelerated paying its suppliers.
Qiagen NV Days Payable Related Terms
Qiagen NV Days Payable Historical Data
* Premium members only.
The historical data trend for Qiagen NV's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:QIA vs TWST, CRL, BLLN: Days Payable Comparison
For the Diagnostics & Research subindustry, Qiagen NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Days Payable distribution charts can be found below:
* The bar in red indicates where Qiagen NV's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Qiagen NV's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a Days Payable of 37.46 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Qiagen NV and its competitors. This is 19% below median its historical median of 46.24. Over the past decade, Qiagen NV's Days Payable has ranged from 30.23 to 58.08. According to the industry distribution chart, Qiagen NV ranks #145 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 76.3%.
Is Qiagen NV's Days Payable too high?
Qiagen NV's current Days Payable of 37.46 is 19% below median its 10-year median of 46.24. Over the past 10 years, this metric has ranged from a low of 30.23 to a high of 58.08. The Medical Diagnostics & Research industry median Days Payable is 65.39. Qiagen NV's value of 37.46 is 42.7% below this industry median. Based on the distribution chart, Qiagen NV ranks #145 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Qiagen NV has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Days Payable compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #145 out of 190 companies for Days Payable. This places Qiagen NV in the lower half of its industry. The industry median Days Payable is 65.39. Qiagen NV's value of 37.46 is 42.7% below this benchmark. Historically, Qiagen NV's own Days Payable has ranged from 30.23 to 58.08 over the past decade. While the company's 10-year median is 46.24 vs. the industry median of 65.39, Qiagen NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qiagen NV's current Days Payable of 37.46 is 42.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Qiagen NV and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qiagen NV's current Days Payable is 37.46, which is 19% below median its own 10-year median of 46.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.46, compared to a current price of €34.63 — trading 23.8% below its estimated fair value. The current Days Payable is 37.46, which is 19% below median its 10-year median of 46.24 and 42.7% below the Medical Diagnostics & Research industry median of 65.39. Qiagen NV's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Days Payable is 37.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €34.63 is trading 23.8% below its estimated GF Value™ of €45.46.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
Days Payable: 37.46 (19% below median its 10-year median of 46.24)
GF Value™: €45.46 vs. price of €34.63 (23.8% below fair value)
Industry Position: 42.7% below the Medical Diagnostics & Research median (#145 of 190)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
69GF Score
Get the complete analysis for XTER:QIA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
